{"generic":"Norethindrone Acetate","drugs":["Aygestin","Norethindrone Acetate"],"mono":{"0":{"id":"410194-s-0","title":"Generic Names","mono":"Norethindrone Acetate"},"1":{"id":"410194-s-1","title":"Dosing and Indications","sub":{"0":{"id":"410194-s-1-4","title":"Adult Dosing","mono":"<ul><li><b>Amenorrhea, Secondary:<\/b> 2.5-10 mg ORALLY daily for 5-10 days during the second half of the theoretical menstrual cycle (after endometrium has been adequately primed with estrogen); adapt dosage to specific indications and therapeutic response of individual patient<\/li><li><b>Dysfunctional uterine bleeding:<\/b> 2.5 to 10 mg ORALLY daily for 5 to 10 days during the second half of the theoretical menstrual cycle (after endometrium has been adequately primed with estrogen); adapt dosage to specific indications and therapeutic response of individual patient<\/li><li><b>Endometriosis:<\/b> initial, 5 mg ORALLY daily for 2 weeks<\/li><li><b>Endometriosis:<\/b> maintenance, increase dose by 2.5 mg per day every 2 weeks until 15 mg daily is reached; administer for 6-9 months or until breakthrough bleeding demands temporary termination; adapt dosage to specific indications and therapeutic response of individual patient<\/li><\/ul>"},"1":{"id":"410194-s-1-5","title":"Pediatric Dosing","mono":"Safety and effectiveness in children not established"},"3":{"id":"410194-s-1-7","title":"Indications","mono":"<b>FDA-Labeled Indications<\/b><ul><li>Amenorrhea, Secondary<\/li><li>Dysfunctional uterine bleeding<\/li><li>Endometriosis<\/li><\/ul><b>Non-FDA Labeled Indications<\/b><br\/>In vitro fertilization; Adjunct<br\/>"}}},"3":{"id":"410194-s-3","title":"Contraindications\/Warnings","sub":[{"id":"410194-s-3-9","title":"Contraindications","mono":"<ul><li>Arterial thromboembolic disease, active or recent (within 12 months)<\/li><li>Carcinoma of the breast, known, suspected, or history of<\/li><li>DVT or pulmonary embolism, active or history of<\/li><li>Hypersensitivity to norethindrone acetate or any component of the product<\/li><li>Liver disease or impaired liver function<\/li><li>Pregnancy<\/li><li>Undiagnosed vaginal bleeding<\/li><li>Use as a diagnostic test for pregnancy<\/li><\/ul>"},{"id":"410194-s-3-10","title":"Precautions","mono":"<ul><li>Cardiovascular:<\/li><li>-- Use cautiously in patients with risk factors for arterial vascular disease or VTE<\/li><li>-- Fluid retention may occur; monitoring recommended in those with epilepsy, migraines, and cardiac or renal dysfunction<\/li><li>Endocrine and Metabolic:<\/li><li>-- Effects on lipid and carbohydrate metabolism have been reported; monitoring recommended for diabetic and hyperlipidemic patients<\/li><li>Ophthalmic:<\/li><li>-- Visual abnormalities may occur; permanent discontinuation may be required<\/li><li>Psychiatric:<\/li><li>-- Worsening or recurring depression has been reported; monitoring recommended and discontinuation may be necessary<\/li><li>Reproductive:<\/li><li>-- Adequately evaluate if undiagnosed vaginal bleeding occurs<\/li><\/ul>"},{"id":"410194-s-3-11","title":"Pregnancy Category","mono":"X (FDA)<br\/>"},{"id":"410194-s-3-12","title":"Breast Feeding","mono":"Micromedex: Infant risk cannot be ruled out.<br\/>"}]},"4":{"id":"410194-s-4","title":"Drug Interactions","sub":[{"id":"410194-s-4-13","title":"Contraindicated","mono":"<ul>Tranexamic Acid (probable)<\/ul>"},{"id":"410194-s-4-14","title":"Major","mono":"<ul><li>Aripiprazole (theoretical)<\/li><li>Carbamazepine (probable)<\/li><li>Dabrafenib (theoretical)<\/li><li>Darunavir (theoretical)<\/li><li>Eliglustat (theoretical)<\/li><li>Fentanyl (theoretical)<\/li><li>Isotretinoin (theoretical)<\/li><li>Theophylline (theoretical)<\/li><li>Tizanidine (probable)<\/li><li>Ulipristal (established)<\/li><\/ul>"},{"id":"410194-s-4-15","title":"Moderate","mono":"<ul><li>Alprazolam (probable)<\/li><li>Amprenavir (probable)<\/li><li>Aprepitant (probable)<\/li><li>Atazanavir (probable)<\/li><li>Bacampicillin (probable)<\/li><li>Betamethasone (probable)<\/li><li>Bexarotene (probable)<\/li><li>Bosentan (probable)<\/li><li>Colesevelam (probable)<\/li><li>Cyclosporine (probable)<\/li><li>Delavirdine (probable)<\/li><li>Etravirine (probable)<\/li><li>Fosamprenavir (established)<\/li><li>Fosaprepitant (probable)<\/li><li>Fosphenytoin (probable)<\/li><li>Griseofulvin (established)<\/li><li>Lamotrigine (established)<\/li><li>Licorice (probable)<\/li><li>Modafinil (probable)<\/li><li>Mycophenolate Mofetil (probable)<\/li><li>Mycophenolic Acid (probable)<\/li><li>Nelfinavir (probable)<\/li><li>Oxcarbazepine (probable)<\/li><li>Phenobarbital (probable)<\/li><li>Phenytoin (probable)<\/li><li>Prednisolone (established)<\/li><li>Primidone (probable)<\/li><li>Rifabutin (probable)<\/li><li>Rifampin (established)<\/li><li>Rifapentine (probable)<\/li><li>Ritonavir (probable)<\/li><li>Rosuvastatin (probable)<\/li><li>Rufinamide (probable)<\/li><li>Selegiline (probable)<\/li><li>St John's Wort (established)<\/li><li>Telaprevir (established)<\/li><li>Topiramate (probable)<\/li><li>Troglitazone (probable)<\/li><li>Troleandomycin (established)<\/li><li>Valdecoxib (probable)<\/li><li>Voriconazole (established)<\/li><li>Warfarin (probable)<\/li><\/ul>"}]},"5":{"id":"410194-s-5","title":"Adverse Effects","mono":"<b>Common<\/b><ul><li><b>Cardiovascular:<\/b>Edema<\/li><li><b>Gastrointestinal:<\/b>Nausea<\/li><li><b>Reproductive:<\/b>Breast tenderness, Irregular periods<\/li><\/ul><b>Serious<\/b><ul><li><b>Hematologic:<\/b>Deep venous thrombosis, Thromboembolic disorder<\/li><li><b>Ophthalmic:<\/b>Optic neuritis<\/li><\/ul>"},"6":{"id":"410194-s-6","title":"Drug Name Info","sub":{"0":{"id":"410194-s-6-17","title":"US Trade Names","mono":"Aygestin<br\/>"},"2":{"id":"410194-s-6-19","title":"Class","mono":"<ul><li>Endocrine-Metabolic Agent<\/li><li>Progestin<\/li><\/ul>"},"3":{"id":"410194-s-6-20","title":"Regulatory Status","mono":"RX<br\/>"},"4":{"id":"410194-s-6-21","title":"Generic Availability","mono":"Yes<br\/>"}}},"7":{"id":"410194-s-7","title":"Mechanism Of Action","mono":"Norethindrone acetate is a synthetic and active progestin with twice the weight-based potency of norethindrone. In an estrogen-primed endometrium, it stimulates secretory changes.<br\/>"},"8":{"id":"410194-s-8","title":"Pharmacokinetics","sub":[{"id":"410194-s-8-23","title":"Absorption","mono":"Tmax, Oral: 1.83 hours <br\/>"},{"id":"410194-s-8-24","title":"Distribution","mono":"<ul><li>Protein binding, Albumin: 61%<\/li><li>Protein binding, Sex hormone-binding globulin: 36%<\/li><li>Vd: Approximately 4 L\/kg<\/li><\/ul>"},{"id":"410194-s-8-25","title":"Metabolism","mono":"<ul><li>Liver: Extensive via reduction then conjugation<\/li><li>Sulfate metabolites: Unknown<\/li><li>Glucuronide metabolites: Unknown<\/li><\/ul>"},{"id":"410194-s-8-26","title":"Excretion","mono":"<ul><li>Renal: Detected, as metabolites<\/li><li>Fecal: Detected, as metabolites<\/li><li>Total body clearance: 0.4 L\/hr\/kg<\/li><\/ul>"},{"id":"410194-s-8-27","title":"Elimination Half Life","mono":"8.51 hours <br\/>"}]},"9":{"id":"410194-s-9","title":"Administration","mono":"<b>Oral<\/b><br\/>take exactly as directed at intervals not exceeding 24 hr <br\/>"},"10":{"id":"410194-s-10","title":"Monitoring","mono":"<ul><li>Improvement in amenorrhea, endometriosis, or abnormal uterine bleeding indicates efficacy<\/li><li>Fluid retention; in patients with conditions that may be affected by this<\/li><li>Worsening or recurring depression<\/li><li>Effects on lipid or carbohydrate metabolism; in patients with diabetes or hyperlipidemia<\/li><\/ul>"},"11":{"id":"410194-s-11","title":"How Supplied","mono":"<ul><li><b>Generic<\/b><br\/>Oral Tablet: 5 MG<br\/><\/li><li><b>Aygestin<\/b><br\/>Oral Tablet: 5 MG<br\/><\/li><\/ul>"},"12":{"id":"410194-s-12","title":"Toxicology","sub":[{"id":"410194-s-12-31","title":"Clinical Effects","mono":"<b>PROGESTINS<\/b><br\/>OVERDOSE:  Rarely do acute ingestions result in obvious clinical manifestations.  CHRONIC: Most  adverse effects are related to chronic or high-dose therapy.  Headache, dizziness, irregular menses, mastalgia, bloating, depression, decreased libido, cholestatic jaundice, hepatitis, oligomenorrhea, amenorrhea and thromboembolism may occur with chronic therapy.<br\/>"},{"id":"410194-s-12-32","title":"Treatment","mono":"<b>PROGESTINS <\/b><br\/><ul><li>Support: Single acute overdoses will seldom result in toxicity.  Supportive treatment is adequate in most situations.<\/li><li>Decontamination: Gastric decontamination is probably only necessary after very large ingestions or with toxic coingestants; administer activated charcoal in these cases.<\/li><li>Monitoring of patient: CHRONIC TOXICITY: Discontinue medication and monitor for signs of toxicity and treat symptomatically.  Obtain a baseline CBC and hepatic and renal function tests in symptomatic patients.<\/li><\/ul>"},{"id":"410194-s-12-33","title":"Range of Toxicity","mono":"<b>PROGESTINS<\/b><br\/>Toxicity is unlikely following an acute overdose.  There are insufficient data reported in the literature to assess the range of toxicity in terms of mg\/kg ingested. <br\/>"}]},"13":{"id":"410194-s-13","title":"Clinical Teaching","mono":"<ul><li>Advise patient that withdrawal bleeding may occur within 3 to 7 days after discontinuing drug therapy.<\/li><li>This drug may cause edema, acne, chloasma, change in weight, headache, depression, abnormal menstruation, breakthrough bleeding, tender or swollen breasts, or scanty vaginal bleeding.<\/li><li>Tell patient to report signs\/symptoms of thromboembolic\/thrombotic disorder or optic neuritis (sudden partial or complete loss of vision, sudden onset of proptosis, diplopia, or migraine).<\/li><\/ul>"}}}